The use of botulinum toxin for the treatment of overactive bladder syndrome

Bogdan Orasanu, Sangeeta T Mahajan, Bogdan Orasanu, Sangeeta T Mahajan

Abstract

Over the last 50 years, botulinum toxin has been transformed from a cause of life-threatening disease to an effective medical therapy. It has been used in a variety of specialties for different indications, significantly improving patient quality of life. A recent growing body of evidence suggests that intra-detrusor injection of botulinum toxin may have beneficial effects in patients with medication refractory detrusor overactivity and may offer a new minimally invasive alternative to patients with severe overactive bladder symptoms. To review current data regarding the effects of botulinum toxin in patients with overactive bladder, a MEDLINE(®)/PubMed(®) literature search was carried out. The mechanism of action, clinical usage, adverse effects, and treatment efficacy were reviewed and the results are presented in this paper.

Keywords: Botulinum toxin; idiopathic detrusor overactivity; lower urinary tract dysfunction; neurogenic detrusor overactivity; overactive bladder; urge incontinence.

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. Simpson D. Clinical trials of botulinum toxin in the treatment of spasticity. Muscle Nerve Suppl. 1997;6:S169–75.
    1. Kleeman SD, Karram MM. Overactive bladder syndrome and nocturia. In: Walters MD, Karam MM, editors. Urogynecology and reconstructive pelvic surgery. 3rd ed. Philadelphia: Mosby; 2007.
    1. Wyman JF, Burgio KL, Newman DK. Practical aspects of life style modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence. Int J Clin Pract. 2009;63:1177–9.
    1. van Ermengem E. Classics in infectious diseases. A new anaerobic bacillus and its relation to botulism. E. van Ermengem. Originally published as “Ueber einen neuen anaëroben Bacillus und seine Beziehungen zum Botulismus” in Zeitschrift für Hygiene und Infektionskrankheiten 26: 1-56, 1897. Rev Infect Dis. 1979;1:701–19.
    1. Mahajan ST, Brubaker L. Botulinum toxin: From life-threatening disease to novel medical therapy. Am J Obstet Gynecol. 2007;196:7–15.
    1. Hallan RI, Williams NS, Melling J, Waldron DJ, Womack NR, Morrison JF. Treatment of anismus in intractable constipation with botulinum A toxin. Lancet. 1988;24:714–7.
    1. [Last accessed february 17, 2013]. Available from: .
    1. Schiavo G, Rossetto O, Santucci A, Dasgupta B, Montecucco C. Botulinum neurotoxins are zinc proteins. J Biol Chem. 1992;267:23479–83.
    1. Simpson L, Dasgupta B. Botulinum neurotoxin type E: Studies on the mechanism of action and on structure activity relationships. J Pharmacol Exp Ther. 1983;224:135–40.
    1. Simpson L. Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther. 1980;212:16–21.
    1. Dolly J. General properties and cellular mechanisms of neurotoxins. In: Jankovic J, Hallet M, editors. Therapy with botulinum toxin. New York: Marcel Dekker; 1994.
    1. Dolly J, Black J, Williams R, Melling J. Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalisation. Nature. 1984;307:457–60.
    1. Dykstra D, Sidi A. Treatment of detrusor sphincter dyssynergia with botulinum A toxin. Arch Phys Med Rehab. 1990;71:24–6.
    1. Holds J, Alderson K, Fogg S, Anderson R. Motor nerve sprouting in human orbicularis muscle after botulinum A injection. Invest Opthalmol Vis Sci. 1990;31:964–96.
    1. Maria G, Cassetta E, Gui D, Brisinda G, Bentivoglio A, Albanese A. A comparison of botulinum toxin and saline for the treatment of chronic anal fissure. N Engl J Med. 1998;338:217–20.
    1. Sahai A, Dowson C, Khan MS, Dasgupta P GKT Botulinum Study Group. Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity. Urology. 2010;75:552–8.
    1. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord. 1994;9:213–7.
    1. Greene P, Fahn S. Development on antibodies to botulinum toxin type A in patients with torticollis treated with injections of botulinum toxin type A. In: Dasgupta B, editor. Boutlinum and tetanus neurotoxins: Neurotransmission and biomedical aspects. New York: Plenum Press; 1993.
    1. Ansved T, Odergren T, Borg K. Muscle fiber atrophy in leg muscles after botulinum toxin type A treatment of cervical dystonia. Neurology. 1997;48:1440–2.
    1. Leippold T, Reitz A, Schurch B. Botulinum toxin as a new therapy option for voiding disorders: Current state of the art. Eur Urol. 2003;44:165–74.
    1. Smith CP, Chancellor MB. Simplified bladder botulinum-toxin delivery technique using flexible cystoscope and 10 sites of injection. J Endourol. 2005;19:880–2.
    1. Apostolidis A, Dasgupta P, Denys P, Elneil S, Fowler CJ, Giannantoni A, et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: A European consensus report. Eur Urol. 2009;55:100–19.
    1. Wyndaele JJ, Van Dromme SA. Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord. 2002;40:599–600.
    1. Smaldone MC, Ristau BT, Leng WW. Botulinum toxin therapy for neurogenic detrusor overactivity. Urol Clin North Am. 2010;37:567–80.
    1. Karsenty G, Denys P, Amarenco G, De Seze M, Gamé X, Haab F, et al. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: A systematic literature review. Eur Urol. 2008;53:275–87.
    1. Kuo HC, Liao CH, Chung SD. Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: Risk factors and influence on treatment outcome. Eur Urol. 2010;58:919–26.
    1. [Last accessed february 17, 2013]. Available from: .
    1. Binder W, Brin M, Blitzer A, Pogoda JM. Botulinum toxin type A (BOTOX) for treatment of migraine. Dis Mon. 2002;48:323–35.
    1. Ginsberg D, Gousse A, Keppenne V, Sievert KD, Thompson C, Lam W, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012;187:2131–9.
    1. Schurch B, Stohrer M, Kramer G, Schmid D, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: A new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000;164:692–7.
    1. Deffontaines-Rufin S, Weil M, Verollet D, Peyrat L, Amarenco G. Botulinum Toxin A for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients. Int Braz J Urol. 2011;37:642–8.
    1. Giannantoni A, Conte A, Proietti S, Giovannozzi S, Rossi A, Fabbrini G, et al. Botulinum toxin type A in patients with Parkinson's disease and refractory overactive bladder. J Urol. 2011;186:960–4.
    1. Herschorn S, Gajewski J, Ethans K, Corcos J, Carlson K, Bailly G, et al. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: A randomized, double-blind trial. J Urol. 2011;185:2229–35.
    1. Khan S, Game X, Kalsi V, Gonzales G, Panicker J, Elneil S, et al. Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis. J Urol. 2011;185:1344–9.
    1. Chen CY, Liao CH, Kuo HC. Therapeutic effects of detrusor botulinum toxin A injection on neurogenic detrusor overactivity in patients with different levels of spinal cord injury and types of detrusor sphincter dyssynergia. Spinal Cord. 2011;49:659–64.
    1. Chen G, Liao L. Injections of botulinum toxin A into the detrusor to treat neurogenic detrusor overactivity secondary to spinal cord injury. Int Urol Nephrol. 2011;43:655–62.
    1. Wefer B, Ehlken B, Bremer J, Burgdörfer H, Domurath B, Hampel C, et al. Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX) therapy in Germany. World J Urol. 2010;28:385–90.
    1. Stoehrer M, Wolff A, Kramer G, Steiner R, Lmöchner-Ernst D, Leuth D, et al. Treatment of neurogenic detrusor overactivity with botulinum toxin A: The first seven years. Urol Int. 2009;83:379–85.
    1. Pannek J, Göcking K, Bersch U. Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction. BJU Int. 2009;104:1246–50.
    1. Ghalayini IF, Al-Ghazo MA, Elnasser ZA. Is efficacy of repeated intradetrusor botulinum toxin type A (Dysport) injections dose dependent? Clinical and urodynamic results after four injections in patients with drug-resistant neurogenic detrusor overactivity. Int Urol Nephrol. 2009;41:805–13.
    1. Giannantoni A, Mearini E, Del Zingaro M, Porena M. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: Clinical and urodynamic results. Eur Urol. 2009;55:705–11.
    1. Ehren I, Volz D, Farrelly E, Berglund L, Brundin L, Hultling C, et al. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: A randomised, placebo-controlled, double-blind study. Scand J Urol Nephrol. 2007;41:335–40.
    1. Schurch B, Denys P, Kozma CM, Reese PR, Slaton T, Barron RL. Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence. Eur Urol. 2007;52:850–8.
    1. Tow AM, Toh KL, Chan SP, Consigliere D. Botulinum toxin type A for refractory neurogenic detrusor overactivity in spinal cord injured patients in Singapore. Ann Acad Med Singapore. 2007;36:11–7.
    1. Karsenty G, Reitz A, Lindemann G, Boy S, Schurch B. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology. 2006;68:1193–7.
    1. Grosse J, Kramer G, Stohrer M. Success of repeat detrusor injections of botulinum A toxin in patients with severe neurogenic detrusor overactivity incontinence. Eur Urol. 2005;47:653–9.
    1. Smith C, Nishiguchi J, O'Leary M, Yoshimura N, Chancellor M. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology. 2005;65:37–41.
    1. Schurch B, de Sèze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, et al. Botulinum toxin type A is a safe and effective treatment for neurogenic incontinence: Results of a single treatment, randmized, placebo controlled 6-month study. J Urol. 2005;174:196–200.
    1. Reitz A, Stöhrer M, Kramer G, Del Popolo G, Chartier-Kastler E, Pannek J, et al. European experience of 200 cases treated with bolutlinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol. 2004;45:510–5.
    1. [Last accessed february 17, 2013]. Available from: .
    1. Denys P, Le Normand L, Ghout I, Costa P, Chartier-Kastler E, Grise P, et al. Efficacy and safety of low doses of botulinum toxin type A for the treatment of refractory idiopathic overactive bladder: A multicenter, double-blind, randomized, placebo-controlled dose-ranging study. Eur Urol. 2012;61:520–9.
    1. Rovner E, Kennelly M, Schulte-Baukloh H, Zhou J, Haag-Molkenteller C, Dasgupta P. Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn. 2011;30:556–62.
    1. Lie KY, Wong MY. Botulinum toxin a for idiopathic detrusor overactivity. Ann Acad Med Singapore. 2010;39:714–5.
    1. Marte A, Borrelli M, Sabatino MD, Balzo BD, Prezioso M, Pintozzi L, et al. Effectiveness of botulinum-A toxin for the treatment of refractory overactive bladder in children. Eur J Pediatr Surg. 2010;20:153–7.
    1. Sahai A, Dowson C, Khan MS, Dasgupta P. Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: Results from a randomized double-blind placebo-controlled trial. BJU Int. 2009;103:1509–15.
    1. Brubaker L, Richter HE, Visco A, Mahajan S, Nygaard I, Braun TM, et al. Pelvic Floor Disorders Network. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol. 2008;180:217–22.
    1. Mohanty NK, Nayak RL, Alam M, Arora RP. Role of botulinum toxin-A in management of refractory idiopathic detrusor overactive bladder: Single center experience. Indian J Urol. 2008;24:182–5.
    1. Jeffery S, Fynes M, Lee F, Wang K, Williams L, Morley R. Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity. BJU Int. 2007;100:1302–6.
    1. Schmid DM, Sauermann P, Werner M, Schuessler B, Blick N, Muentener M, et al. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol. 2006;176:177–85.
    1. Werner M, Schmid DM, Schüssler B. Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: A prospective nonrandomized study. Am J Obstet Gynecol. 2005;192:1735–40.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe